Screener
MBX Biosciences, Inc. MBX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 14,567 | 15,495 |
| Share repurchase liability | 1 | 2 |
| Operating lease liability, net of current | 377 | 424 |
| Total liabilities | 14,945 | 15,921 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized and zero issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value, 500,000,000 shares authorized and 47,570,464 issued and outstanding as of March 31, 2026 and 500,000,000 shares authorized and 44,927,953 issued and outstanding as of December 31, 2025 | 6 | 6 |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s total liabilities?
- MBX Biosciences, Inc. (MBX) reported total liabilities of $14.95M in Q1 2026.
- How has MBX Biosciences, Inc.'s total liabilities changed year-over-year?
- MBX Biosciences, Inc.'s total liabilities increased by 42.3% year-over-year, from $10.5M to $14.95M.
- What is the long-term trend for MBX Biosciences, Inc.'s total liabilities?
- Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s total liabilities has grown at a 92.6% compound annual growth rate (CAGR), from $4.29M to $15.92M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about MBX Biosciences, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude